


LISTING OF CLAIMS

CLAIMS

We claim:

1. (Currently amended): A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein

Y is

- a) -NHC(=W)R¹,
- b) -O-het, -S-het, or -NH-het;

X is

- a) -NR³-,
- a) -O-,
- b) -S(=O)_i-, or
- c) -S(=O)(=NR⁴)-;

W is

- a) O, or
- b) S;

R¹ is

- a) H,
- b) C₁₋₈alkyl,
- c) C₃₋₆cycloalkyl,
- d) OC₁₋₄ alkyl,
- e) SC₁₋₄ alkyl,

- f) NH₂,
- g) NHC₁₋₆ alkyl, or
- h) N(C₁₋₆ alkyl)₂;

R² is

- a) H,
- b) halo, or
- c) C₁₋₄ alkyl;

R³ is

- a) H,
- b) C₁₋₈alkyl,
- c) aryl,
- d) het,
- e) C(=W)R⁵,
- f) C(=O)OR⁶, or
- g) S(=O)_iR⁷;

R⁴ is

- a) H, or
- b) C₁₋₈alkyl;

R⁵ is

- a) H,
- b) aryl,
- c) het,
- d) NR⁸R⁹, or
- e) C₁₋₈alkyl;

R⁶ is

- a) C₁₋₈alkyl,
- b) aryl, or
- c) het;

R⁷ is

- a) aryl,

- b) het,
- c) NR⁸R⁹, or
- d) C₁₋₈alkyl;

R⁸ and R⁹ are independently

- a) H,
- b) C₁₋₈alkyl, or
- c) aryl;

wherein >G-E is >C=C- and Q is a nitrogen atom;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;

het is a C-linked five- (5) or six- (6) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring;

at each occurrence, alkyl or cycloalkyl is optionally substituted with one or more OR⁸, halo, aryl, S(=O)_iR⁷, C(=W)R⁸, OC(=O)C₁₋₆alkyl, or NR⁸R⁹;

at each occurrence, aryl is optionally substituted with one or more halo, OH, CF₃, OC₁₋₆alkyl, CN, C₁₋₆alkyl, S(=O)_iR⁷, C(=W)R⁸, OC(=O)R⁸, NHC(=O)R⁸, or NR⁸R⁹;


at each occurrence, het is optionally substituted with one or more halo, OH, CF₃, OC₁₋₆alkyl, CN, C₁₋₆alkyl, S(=O)_iR⁷, C(=W)R⁸, OC(=O)R⁸, NHC(=O)R⁸, or NR⁸R⁹, oxo, or oxime;

m is 0, 1, 3, or 4;

n is 0, 1, 3, or 4; with the proviso that m and n taken together are 3 or 4; if m is 2 n is not 2, and if n is 2 m is not 2; and

i is 0, 1, or 2.


2. (original): A compound of claim 1 which is a compound of formula IA:



IA.

3. (original): A compound of claim 2 wherein R² is H.
4. (original): A compound of claim 2 wherein R¹ is C₁₋₆alkyl.
5. (original): A compound of claim 2 wherein R¹ is methyl.
6. (original): A compound of claim 4 wherein R³ is C(=O)R⁵, or C(=O)OR⁵.
7. (original): A compound of claim 4 wherein R³ is C(=O)CH₂OH.
8. (original): A compound of claim 4 wherein R³ is CHO.
9. (original): A compound of claim 4 wherein R⁵ is C₁₋₄alkyl, optionally substituted with C(=O)C₁₋₄alkyl, OC(=O)C₁₋₄alkyl, C(=O)phenyl, or phenyl, wherein said phenyl is optionally substituted with I, or CF₃.
10. (original): A compound of claim 4 wherein R⁵ is phenyl.
11. (original): A compound of claim 4 wherein R³ is C(=S)R⁵, wherein R⁵ is aryl, alkyl or NR⁸R⁹, wherein R⁸ and R⁹ are independently H, C₁₋₄alkyl or aryl.
12. (original): A compound of claim 4 wherein R³ is S(=O)_iC₁₋₄alkyl,
13. (original): A compound of claim 4 wherein R³ is H, C₁₋₈alkyl, or aryl, .
14. (original): A compound of claim 4 or 6 wherein m is 1 and n is 3.
15. (original): A compound of claim 4 or 6 wherein m is 0 and n is 4.


16. (original): A compound of claim 4 or 6 wherein m is 1 and n is 2.
17. (original): A compound of claim 4 or 6 wherein m is 2 and n is 1.
18. (original): A compound of claim 1 which is a compound of formula IB:



IB


wherein A is O, S or NH and het is isoxazol-3-yl, isoxazol-5-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl, 1,2,4-thiadiazol-3-yl or 1,2,5-thiadiazol-3-yl.

19. (original): A compound of claim 1 which is a compound of formula IC:



IC.

20. (original): A compound of claim 1 which is a compound of formula ID




ID

wherein A is O, S or NH and het is isoxazol-3-yl, isoxazol-5-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl, 1,2,4-thiadiazol-3-yl or 1,2,5-thiadiazol-3-yl.

21. (original): A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of claim 1.
22. (original): The method of claim 21 wherein said compound is administered orally, parenterally, transdermally, or topically.
23. (original): The method of claim 21 wherein said compound is administered in an amount of from about 0.1 to about 150 mg/kg of body weight/day.
24. (original): The method of claim 21 wherein said compound is administered in an amount of from about 3 to about 100 mg/kg of body weight/day.
25. (original): The method of claim 21 wherein said infection is skin infection.
26. (original): The method of claim 21 wherein the infection is eye infection.
27. (original): A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
28. (original): The method of claim 21 wherein said compound is administered in an amount of 600mg per day by IV or by oral.
29. (original): The method of claim 21 wherein said mammal is human.

Respectfully submitted,



John H. Engelmann

Registration No. 28,075

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (269) 833-2532 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316

Date: JUNE 22, 2004